Xlash
Xlash
- Xlash (bimatoprost eyelash serum) can be purchased from some pharmacies and numerous online retailers; although bimatoprost is officially prescription-only in many countries, Xlash is commonly sold without a prescription or receipt by certain vendors and pharmacies.
- Bimatoprost is used to lower intraocular pressure in glaucoma/ocular hypertension and to enhance eyelash growth; it is a prostaglandin analogue that increases aqueous humour outflow and stimulates eyelash follicles to prolong the growth (anagen) phase and increase hair thickness and pigmentation.
- Usual dosages: for eyelash enhancement use 0.03% solution applied once nightly to the upper eyelid margin with an applicator; for glaucoma the standard ophthalmic dose is one drop of 0.03% in the affected eye(s) once daily in the evening.
- Form of administration: ophthalmic solution supplied in a dropper (commonly 3 mL); administered as an eye drop for intraocular pressure or applied with a sterile applicator along the upper lash line for cosmetic use.
- Onset time: ocular pressure-lowering effects may begin within days to weeks; eyelash growth is usually noticeable after about 8 weeks, with more pronounced results by 12–16 weeks.
- Duration of action: for glaucoma the effect is sustained with once-daily dosing (around 24 hours); for eyelash enhancement results persist only with continued use and gradually reverse after treatment is stopped.
- Alcohol warning: there is no specific contraindication with alcohol, but avoid excessive alcohol as it may worsen ocular dryness or irritation and increase risk of adverse effects; follow medical advice if you have other conditions or are taking other medicines.
- The most common side effect is conjunctival hyperemia (eye redness); other common effects include eye irritation, eyelash and eyelid skin changes, and occasional blurred vision or dry eye.
- Would you like to try xlash without a prescription?
Basic Xlash Information
- INN (International Nonproprietary Name): Bimatoprost is the INN for Careprost.
- Brand Names Available In United Kingdom: Careprost, Lumigan, Latisse, plus other international generics such as Carelid and Apo‑Bimatoprost (availability and licence status vary by product and supplier).
- ATC Code: S01EE03 — 'S01' ophthalmologicals, 'EE' prostaglandin analogues, '03' specific for bimatoprost.
- Forms & Dosages: Ophthalmic solution 0.03% w/v in 3 mL dropper vials intended for glaucoma, ocular hypertension and eyelash enhancement when used topically as instructed.
- Manufacturers In United Kingdom: Not specified in source data; major manufacturers cited in the product information include Sun Pharmaceutical Industries Ltd. (India) and Allergan/AbbVie (USA/EU).
- Registration Status In United Kingdom: Not specified in source data; bimatoprost as a substance is registered in many EU countries, while specific product licences should be checked with the MHRA and local formularies.
- OTC / Rx Classification: Prescription‑only (Rx) in most major jurisdictions according to source data; some online vendors supply Careprost without prescription which bypasses regulatory channels.
Latest Research Highlights (UK & EU, 2022–2025)
Patients and clinicians ask: does bimatoprost still do what the trials promised?
Recent UK and EU literature from 2022–2025 continues to support two main uses of bimatoprost: lowering intraocular pressure for glaucoma and ocular hypertension, and eyelash enhancement when used topically.
Real‑world registries and cohort analyses in Europe show prostaglandin analogues remain first‑line for chronic IOP control, consistent with longstanding practice.
Bimatoprost delivers comparable or marginally greater IOP lowering versus some prostaglandin peers in these reports, with the usual caveat that individual response varies.
Safety data since 2022 remain steady and consistent with earlier pivotal trials.
Local ocular effects such as conjunctival hyperaemia, eyelash and eyebrow changes, and peri‑ocular skin darkening are commonly reported.
Iris pigmentation change is rare in the datasets but often permanent when it occurs.
European real‑world summaries echo product information that the standard 0.03% ophthalmic solution is supplied in 3 mL vials and that eyelash regimens involve nightly upper‑lid application with full cosmetic effect by 12–16 weeks.
There have been no new major systemic safety signals in UK/EU pharmacovigilance reports from 2022–2025.
Clinical Effectiveness In The UK
What do NHS clinics and patients say about results in routine care?
- IOP Reduction: Prostaglandin analogues, including bimatoprost, provide reliable once‑daily evening reduction in intraocular pressure sufficient in many cases to delay surgery.
- Adherence Rates: Adherence is generally good when pharmacists or nurses provide clear counselling on nightly dosing and side‑effect expectations.
- Patient‑Reported Outcomes: Some patients report improved ocular comfort; off‑label cosmetic users report noticeable eyelash gains.
- Discontinuation Reasons: Redness and peri‑ocular skin darkening are common causes for stopping treatment in a minority of patients.
| Endpoint | Clinical Use (Glaucoma) | Cosmetic Use (Eyelashes) |
|---|---|---|
| Primary Goal | Lower Intraocular Pressure | Increase Lash Length/Thickness |
| Typical Timeline | Measure IOP response over weeks to months | Visible change ~8 weeks; full effect 12–16 weeks |
| Common Adverse Events | Conjunctival hyperaemia, irritation | Eyelash growth, peri‑ocular darkening, local irritation |
Best practice in NHS secondary care is to monitor IOP response and document any iris colour change in the patient record.
Indications And Expanded Uses
Which uses are licensed and when is off‑label considered?
- Licensed Indication: Bimatoprost formulations are licensed for glaucoma and ocular hypertension and are classified under ATC S01EE03.
- Cosmetic / Off‑Label: Eyelash enhancement is commonly managed either via separate licensed cosmetic products (for example Latisse in other jurisdictions) or as off‑label use of ophthalmic solution after clinician discussion and informed consent.
- When To Refer: Refer to ophthalmology before starting if the patient has active intraocular inflammation (uveitis), is aphakic or pseudophakic, or has complex ocular comorbidity.
Community clinicians should verify MHRA product licences for the specific formulation before prescribing or supplying.
Composition And Brand Landscape
Which brands might patients encounter and what do they contain?
| Brand | Region | Pack Size | Typical Indication |
|---|---|---|---|
| Careprost | India, Global E‑shops | 3 mL dropper vial | Eyelash enhancement; labelled as ophthalmic solution |
| Lumigan | USA, EU | 2.5 mL, 5 mL vial | Glaucoma / Ocular Hypertension |
| Latisse | Global (branded cosmetic) | 3 mL with applicators | Cosmetic eyelash growth (branded product) |
The active ingredient across branded and generic products is bimatoprost (INN).
Sun Pharmaceutical Industries Ltd. is a major manufacturer of Careprost according to product information, while Allergan/AbbVie produce Lumigan and Latisse in the USA/EU.
UK pharmacies will encounter branded imports, licensed EU versions and generics; check the MHRA licence status before dispensing.
Contraindications And Special Precautions
Who should definitely not use bimatoprost and who needs caution?
- Absolute Contraindication: Known hypersensitivity to bimatoprost or any excipient in the formulation.
- Relative Contraindications: History of uveitis, aphakia/pseudophakia (higher macular oedema risk), active ocular infection, immunosuppression, pregnancy and breastfeeding (use not recommended).
- Elderly And Paediatric Use: No routine dose adjustment for elderly patients but monitor for systemic effects; paediatric use is not established.
When to delay treatment: defer initiation if there is active ocular inflammation, an unresolved infection, or uncertain pregnancy status.
Report suspected serious reactions to the MHRA Yellow Card scheme.
Dosage Guidelines
How are glaucoma and eyelash regimens typically written and explained?
| Indication | Form | Dose | Frequency | Monitoring |
|---|---|---|---|---|
| Glaucoma / Ocular Hypertension | 0.03% Ophthalmic Solution | One drop in affected eye(s) | Once daily, evening | Regular IOP checks; ocular surface assessment |
| Eyelash Enhancement | 0.03% Ophthalmic Solution applied with applicator | Apply a single drop with a sterile applicator to upper‑lid margin only | Once nightly | Assess local skin reaction and pigmentation; cosmetic effect by 12–16 weeks |
Missed dose advice: apply when remembered unless close to the next dose; do not double dose.
Contact lenses should be removed before instillation and reinserted after at least 15 minutes.
Interactions Overview
Will bimatoprost mix badly with other medicines or foods?
Systemic food and drink interactions with topical bimatoprost are minimal according to product information.
Alcohol has no specific pharmacokinetic interaction but may worsen ocular dryness and surface irritation.
Ocular drug interactions are most relevant; combining topical glaucoma agents is common but increases the preservative and ocular surface burden.
| Concurrent Ocular Drugs | Monitoring Tips |
|---|---|
| Latanoprost, Travoprost, Tafluprost | Watch for additive ocular surface effects and document reason for switching or combining. |
| Topical Beta Blockers, Carbonic Anhydrase Inhibitors | Monitor IOP response and systemic tolerance where applicable. |
MHRA Yellow Card reports highlight local ocular events (hyperaemia, itching) more commonly than systemic adverse drug reactions.
Encourage reporting of suspected adverse interactions via the Yellow Card to support local surveillance.
Cultural Perceptions And Patient Habits
What do UK patients read on forums and what role do pharmacies play?
- Forum Sentiments: Threads on Patient.info, Mumsnet and social media praise eyelash gains but commonly express anxiety about permanent iris colour change and peri‑orbital darkening.
- Pharmacy Role: Community pharmacists at Boots, LloydsPharmacy and Superdrug are trusted for product selection, storage advice and safe‑use counselling.
- Access Concerns: Online sales of imported Careprost without prescription are a frequent patient worry due to variable quality and regulatory oversight.
| Trusted Sources | Risk Sources |
|---|---|
| Local GP, NHS 111, Community Pharmacy, Ophthalmology Clinic | Unregulated online vendors supplying imported product without prescription |
Pharmacists should practise shared decision‑making, especially for cosmetic enquiries, and document counselling and consent where off‑label use is considered.
Availability And Pricing Patterns
How do patients get bimatoprost in the UK and what does it cost?
Availability: Branded and generic bimatoprost products appear in community pharmacies and private clinics.
Prescription Status: Bimatoprost is prescription‑only in major jurisdictions, but some online vendors supply Careprost without prescription which bypasses UK oversight.
Pricing: NHS prescriptions in England carry the standard NHS item charge unless a patient has an exemption; prescriptions are free in Scotland, Wales and Northern Ireland creating regional cost differences.
Private cosmetic prescriptions and single‑item purchases vary across clinics and online vendors in price.
In our online pharmacy, xlash is available without a prescription, with discreet delivery to United Kingdom in 5‑14 days.
| Source | Typical Access | Regulatory Risk | Likely Cost |
|---|---|---|---|
| NHS Prescription | Via GP or ophthalmology clinic | Low if product is MHRA‑licensed | Standard NHS prescription charge (England) or free (other UK nations) |
| Community Pharmacy | Stocked or ordered; dispenses Rx products | Low when prescription is valid | Variable; typically lower than private clinic for Rx items |
| Private Clinic / Cosmetic | Private prescription and supply | Moderate; depends on product licence | Higher; clinic fees apply |
| Online Import Vendors | Often supply without prescription | Higher regulatory risk; products may bypass MHRA checks | Variable; sometimes cheaper but riskier |
Comparable Medicines And Prescribing Preferences
What else is used on NHS formularies and how do choices get made?
- Common Alternatives: Latanoprost (Xalatan), Travoprost (Travatan) and Tafluprost (Saflutan) are typical options on NHS formularies.
- Formulary Factors: Choice depends on local formulary guidance, patient tolerability, specific IOP response and cost considerations.
- When To Choose Bimatoprost: Consider bimatoprost where an individual patient demonstrates better IOP response or when eyelash effects are acceptable or desired.
| Medicine | Efficacy | Common ADRs | Cost Consideration |
|---|---|---|---|
| Bimatoprost | Strong IOP lowering; sometimes marginally greater | Hyperaemia, eyelash growth, peri‑ocular pigmentation | Variable; branded more expensive than generics |
| Latanoprost | Effective first‑line for many trusts | Hyperaemia, eyelash changes less prominent | Often preferred due to cost and familiarity |
Document the reason for switching agents in clinical records to support continuity of care.
Frequently Asked Questions
- Can I buy Careprost without a prescription in the UK? Legally, bimatoprost products are prescription‑only; online sellers offering Careprost without prescription operate outside normal UK regulatory channels and should be approached with caution.
- Will it change my eye colour permanently? Rarely, prostaglandin analogues can increase iris pigmentation (typically brown) and this change may be permanent; discuss the risk before starting treatment.
- How long until my eyelashes improve? Cosmetic improvement is typically visible after about eight weeks with full effect by 12–16 weeks; continued nightly use is required to maintain results.
- Can I use it with contact lenses? Remove contact lenses before instillation and wait at least 15 minutes before reinserting lenses.
If vision changes or severe irritation occurs, advise patients to contact NHS 111 or their eye emergency service without delay.
Guidelines For Proper Use
What should pharmacists demonstrate and record when advising patients?
- Confirm the indication and that the prescription is legitimate and MHRA‑appropriate where required.
- Explain exact dosing: one drop 0.03% once nightly into affected eye(s) for glaucoma, or single applicator nightly to the upper‑lid margin for cosmetic use.
- Demonstrate application: tilt head back, instil one drop, avoid touching the eye with the bottle and blot excess with a tissue.
- Advise contact lens users to remove lenses before application and wait at least 15 minutes before reinserting.
- Describe common side effects: conjunctival hyperaemia, eye irritation, eyelash/eyebrow changes and peri‑ocular skin darkening.
- Flag rare but significant risks such as iris pigmentation and advise patients this may be permanent.
- Storage: store at room temperature (15–25°C), protect from light and use within four weeks of opening to avoid contamination.
- Provide written patient information, signpost to NHS patient portals and local ophthalmology contacts, and advise Yellow Card reporting for suspected serious ADRs.
For cosmetic enquiries, ensure informed consent is documented and explain that eyelash gains reverse on cessation while iris pigmentation may not.
Delivery Across United Kingdom
| City | Region | Delivery Time |
|---|---|---|
| London | Greater London | 5-7 days |
| Birmingham | West Midlands | 5-7 days |
| Manchester | Greater Manchester | 5-7 days |
| Glasgow | Scotland | 5-7 days |
| Leeds | West Yorkshire | 5-7 days |
| Liverpool | Merseyside | 5-7 days |
| Bristol | South West England | 5-7 days |
| Edinburgh | Scotland | 5-7 days |
| Cardiff | Wales | 5-7 days |
| Belfast | Northern Ireland | 5-7 days |
| Newcastle Upon Tyne | North East England | 5-7 days |
| Sheffield | South Yorkshire | 5-9 days |
| Plymouth | Devon | 5-9 days |